PharmaCyte Biotech, Inc.
PMCB · NASDAQ
4/30/2025 | 4/30/2024 | 4/30/2023 | 4/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $438 | $407 | $469 | $691 |
| G&A Expenses | $3,939 | $4,790 | $4,752 | $2,156 |
| SG&A Expenses | $3,939 | $6,113 | $5,987 | $3,701 |
| Sales & Mktg Exp. | $0 | $1,322 | $1,235 | $1,545 |
| Other Operating Expenses | $0 | -$0 | -$0 | -$0 |
| Operating Expenses | $4,378 | $6,520 | $6,455 | $4,392 |
| Operating Income | -$4,378 | -$6,520 | -$6,455 | -$4,392 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $35,034 | $6,854 | $2,140 | $153 |
| Pre-Tax Income | $30,656 | $334 | -$4,316 | -$4,239 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $30,656 | $334 | -$4,316 | -$4,239 |
| % Margin | – | – | – | – |
| EPS | 3.19 | -1.8 | -0.22 | -0.27 |
| % Growth | 277.2% | -718.2% | 18.5% | – |
| EPS Diluted | 3.19 | -1.8 | -0.83 | -0.79 |
| Weighted Avg Shares Out | 7,330 | 9,581 | 19,489 | 15,522 |
| Weighted Avg Shares Out Dil | 7,330 | 9,581 | 5,178 | 5,178 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,416 | $3,399 | $1,937 | $158 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $0 | $6,520 | $6,455 | $0 |
| EBITDA | $30,656 | $6,854 | -$4,316 | -$4,239 |
| % Margin | – | – | – | – |